Pathology Laboratories

Global Pathology Laboratories Market to Reach US$564.8 Billion by 2030

The global market for Pathology Laboratories estimated at US$374.7 Billion in the year 2024, is expected to reach US$564.8 Billion by 2030, growing at a CAGR of 7.1% over the analysis period 2024-2030. Hospital-based Laboratories, one of the segments analyzed in the report, is expected to record a 6.7% CAGR and reach US$316.8 Billion by the end of the analysis period. Growth in the Standalone Labs segment is estimated at 8.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$102.1 Billion While China is Forecast to Grow at 11.0% CAGR

The Pathology Laboratories market in the U.S. is estimated at US$102.1 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$117.7 Billion by the year 2030 trailing a CAGR of 11.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.6% and 6.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.7% CAGR.

Global Pathology Laboratories Market - Key Trends & Drivers Summarized

Is Pathology the Backbone of Modern Healthcare? The Expanding Role of Diagnostic Laboratories

Pathology laboratories serve as the cornerstone of modern healthcare, playing a pivotal role in disease diagnosis, prognosis, and treatment planning. With the increasing burden of chronic diseases such as cancer, diabetes, and cardiovascular disorders, the demand for accurate and timely diagnostics has surged. Pathology labs provide critical insights into disease pathology, allowing physicians to make informed decisions about patient care. The advent of precision medicine, which relies on molecular and genetic diagnostics, has further propelled the significance of pathology laboratories. These labs are no longer just centers for routine blood work; they now integrate sophisticated technologies such as digital pathology, AI-powered diagnostic tools, and next-generation sequencing (NGS) to enhance accuracy and efficiency. The COVID-19 pandemic highlighted the indispensable role of pathology labs in disease surveillance and outbreak management, further driving investment in diagnostic infrastructure. Governments and healthcare providers worldwide are prioritizing laboratory expansion, accreditation, and automation to meet the rising demand for high-quality diagnostic services. With an increasing emphasis on early disease detection, preventive healthcare, and personalized treatment approaches, pathology laboratories are undergoing a transformative shift towards high-throughput testing and advanced data analytics.

How Is Technology Reshaping the Future of Pathology? AI, Automation & Digital Diagnostics

The integration of artificial intelligence (AI), automation, and digital pathology is revolutionizing the landscape of diagnostic laboratories, making pathology services more accurate, efficient, and scalable. AI-powered image analysis tools are enhancing the interpretation of biopsy samples, enabling faster and more precise cancer detection. Digital pathology, which involves the scanning and digitization of pathology slides, is facilitating remote diagnostics, telepathology, and AI-driven assessments, reducing turnaround times and eliminating geographical barriers. Laboratory automation is streamlining workflows by integrating robotic sample processing, high-speed analyzers, and cloud-based data management systems, reducing human error and improving diagnostic throughput. The implementation of machine learning algorithms in pathology is enhancing predictive analytics, allowing for earlier disease detection and risk assessment. Advances in molecular diagnostics, including polymerase chain reaction (PCR) and gene sequencing technologies, are expanding the capabilities of pathology labs, enabling targeted therapies and personalized medicine. Liquid biopsy technology, which detects cancer biomarkers from blood samples, is emerging as a groundbreaking innovation in pathology, offering a non-invasive alternative to traditional biopsies. As pathology labs move towards fully automated, AI-assisted diagnostic models, the future of pathology is poised to be more data-driven, precise, and patient-centric.

Who Are the Key Players in the Pathology Market? Expanding Accessibility Across Sectors

The pathology laboratory market is witnessing significant expansion across hospitals, independent diagnostic chains, academic research institutions, and government health agencies. Hospital-based pathology labs remain dominant, as they provide in-house diagnostic services to support clinical and surgical departments. Independent diagnostic chains, such as Quest Diagnostics, LabCorp, and Eurofins, are expanding their footprint through acquisitions and partnerships, offering a wide array of specialized tests. The growing prominence of at-home diagnostic services is fueling the demand for direct-to-consumer pathology testing, where patients can order tests online and receive results digitally. Academic and research institutions are increasingly investing in pathology labs to support clinical trials, biomarker discovery, and translational research in precision medicine. Governments across various countries are expanding public pathology services to improve access to diagnostics in rural and underserved areas. The demand for specialized pathology services, such as histopathology, cytopathology, and molecular diagnostics, is rising, driven by the increasing prevalence of cancer, infectious diseases, and genetic disorders. Additionally, the integration of pathology labs with digital health ecosystems and electronic medical records (EMRs) is enhancing diagnostic accessibility and data sharing across healthcare networks.

The Growth in the Pathology Laboratories Market Is Driven by Several Factors…

The increasing prevalence of chronic diseases, particularly cancer, cardiovascular diseases, and infectious diseases, is a major driver of the pathology laboratory market. The rapid adoption of AI-powered diagnostic tools and digital pathology solutions is enhancing diagnostic accuracy and reducing human error, fueling market expansion. The growing demand for personalized medicine and precision diagnostics is driving investment in molecular pathology and genetic testing services. The rise of telemedicine and remote diagnostic capabilities is increasing accessibility to pathology services, particularly in rural and underserved regions. Government initiatives aimed at strengthening healthcare infrastructure and improving diagnostic accuracy are supporting the expansion of pathology laboratories worldwide. The increasing penetration of private diagnostic chains and the consolidation of independent laboratories are leading to economies of scale, making diagnostic services more affordable and efficient. The surge in demand for at-home and direct-to-consumer testing services is reshaping the pathology market, offering convenience and rapid test results to consumers. The growing emphasis on early disease detection, preventive healthcare, and routine screening programs is further driving the adoption of pathology services. Strategic collaborations between healthcare providers, pharmaceutical companies, and diagnostic labs are fostering the development of novel biomarkers and diagnostic tests. As healthcare systems continue to modernize, the pathology laboratory market is set for robust growth, transforming diagnostics into a more technology-driven and patient-focused domain.

SCOPE OF STUDY:

The report analyzes the Pathology Laboratories market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Type (Hospital-based Laboratories, Standalone Labs, Diagnostic Chains); Testing Service (General Physiological & Clinical Tests, Imaging & Radiology Tests, Esoteric Tests, COVID-19 Tests); End-Use (Physician Referrals End-Use, Walk-ins End-Use, Corporate End-Use)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

• Applied BioCode
• BioReference Laboratories
• Centro de Diagnósticos Brasil
• Dr. Lal PathLabs
• Eurofins Scientific
• Exact Sciences Laboratories LLC
• Falco Holdings Co., Ltd.
• Healius Limited
• KingMed Diagnostics
• Laboratory Corporation of America Holdings (Labcorp)
• Metropolis Healthcare
• Nordic Bioscience
• PathGroup
• Quest Diagnostics Incorporated
• Roche Diagnostics
• Siemens Healthineers
• Sonic Healthcare Limited
• Spectra Laboratories
• SYNLAB International GmbH
• Unilabs

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.